

BMT CTN 0102 Auto/auto vs Auto/non-myeloablative Allo PBSCT for Myeloma


Objective

- Compare PFS at 3 years after:
 - Tandem auto vs. auto followed by matched non-myeloablative allo
 - Tandem auto followed by maintenance therapy vs. tandem auto followed by observation

Eligibility

- Meet DS criteria for MM
- MM with symptoms receiving at least 3 cycles therapy, and who are within 2-10 months of initial treatment
- Adequate (≥ 4x10⁶) autograft available
 OR ≥ 2x10⁶ and a matched sib
- Age ≤ 70 years

TREATMENT SCHEMA



To view the entire protocol, go to http://www.bmtctn.net or the PDQ website at http://cancer.gov/clinicaltrials/BMTCTN-0102